Back

Samsung Bioepis secures Nexatecan3 rights for three ADC substances

Verifying
  • Samsung Bioepis secured exclusive Frontline rights to use Intocell’s Nexatecan3 payload.
  • Samsung Bioepis can apply Nexatecan3 to a maximum of three substances.
  • SBE303 is in global Phase 1 trials as the collaboration’s first Nexatecan3 drug.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.